DBV Technologies (DBVT) to Release Earnings on Thursday

DBV Technologies (NASDAQ:DBVT) is expected to release its earnings data before the market opens on Thursday, March 6th. Analysts expect DBV Technologies to post earnings of ($0.31) per share and revenue of $1.08 million for the quarter.

DBV Technologies Price Performance

DBV Technologies stock opened at $4.19 on Thursday. The firm has a 50 day simple moving average of $4.06 and a 200-day simple moving average of $3.83. The stock has a market capitalization of $86.18 million, a PE ratio of -0.93 and a beta of 0.67. DBV Technologies has a 12-month low of $2.20 and a 12-month high of $9.09.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on DBVT. JMP Securities reiterated a “market outperform” rating and issued a $10.00 price objective on shares of DBV Technologies in a report on Friday, January 10th. StockNews.com started coverage on shares of DBV Technologies in a research note on Wednesday. They set a “hold” rating for the company.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.